Lebetin peptides: potent platelet aggregation inhibitors

Area of Science:

• Biochemistry
• Pharmacology
• Toxicology

Background:

• Lebetins, peptides from *Macrovipera lebetina* snake venom, represent a new category of platelet aggregation inhibitors.
• These peptides exist in two forms: lebetin 1 (L1; 11-13 amino acids) and lebetin 2 (L2; 37-38 amino acids), with shorter lebetins being N-terminal segments of longer ones.

Purpose of the Study:

• To investigate the antiplatelet aggregation activity of lebetins.
• To identify key residues influencing the activity of lebetin 1 (L1) through alanine scanning.
• To explore the potential of multimeric lebetin constructs for enhanced antiplatelet efficacy.

Main Methods:

• Synthesis and characterization of native and truncated lebetin peptides.
• Alanine scanning mutagenesis to probe structure-activity relationships of synthetic L1gamma (sL1gamma).
• In vitro evaluation of antiplatelet activity against various agonists (thrombin, collagen, PAF-acether).
• Synthesis of multimeric L1gamma peptides using a multiple-antigen peptide system.

Main Results:

• Lebetins effectively inhibit platelet aggregation induced by thrombin, collagen, and PAF-acether.
• The shortest lebetin (11-mer) demonstrates potent inhibition of both rabbit (IC50 = 7 nM) and human (IC50 = 5 nM) platelets.
• Alanine substitution studies identified critical residues (P3, G7, P8, P9, N10) for activity and others (K2, P4, K6) that enhance it.
• Multimeric L1gamma peptides exhibited up to a 1,000-fold increase in antiplatelet activity compared to monomeric forms.

Conclusions:

• Lebetins are potent inhibitors of platelet aggregation with potential therapeutic value.
• Specific amino acid residues in lebetins are crucial for their antiplatelet function.
• Multimerization of lebetins significantly potentiates their antiplatelet activity, suggesting a promising strategy for drug development.